<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32011508</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Incomplete recovery from rocuronium-induced muscle relaxation in patients with amyotrophic lateral sclerosis using sugammadex: A case report.</ArticleTitle><Pagination><StartPage>e18867</StartPage><MedlinePgn>e18867</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e18867</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000018867</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patients with motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), have higher sensitivity to nondepolarizing neuromuscular blocking agents (NMBAs) and are at higher risk for a residual block. For this reason, the use of NMBAs such as rocuronium has been limited owing to the delayed reversal of muscle relaxation. It was recently reported that rapid and effective reversal of muscle relaxation occurs when sugammadex, a muscle relaxant reversal drug, is administered to patients in ALS with rocuronium-induced muscle relaxation. However, in this paper, we report the incomplete recovery and recurarization of muscle relaxation after sugammadex administration in ALS patients, and delayed recovery of muscle relaxation after additional administration of sugammadex.</AbstractText><AbstractText Label="PATIENT CONCERNS" NlmCategory="METHODS">A 71-year-old male patient with ALS received general anesthesia for laparoscopic nephroureterectomy.</AbstractText><AbstractText Label="DIAGNOSIS" NlmCategory="METHODS">The patient was diagnosed with ALS 2 years earlier, and scheduled to undergo laparoscopic nephroureterectomy for ureteral cancer.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">We used sugammadex for the reversal of deep neuromuscular block. We measured a train-of-four (TOF) count of 4 and a TOF ratio of 54% at about 8&#x200a;min after administration of 4&#x200a;mg/kg sugammadex. However, then the TOF count decreased to 1 to 3 and tidal volume (TV) decreased to &lt; 100&#x200a;mL. Therefore, an additional 50&#x200a;mg sugammadex was administered intravenously 12&#x200a;min after the first dose of sugammadex was injected.</AbstractText><AbstractText Label="OUTCOMES" NlmCategory="RESULTS">The patient's vital signs were stable and his recovery from anesthesia was uneventful. Therefore, he was discharged to the intensive care unit. The patient had aspiration pneumonia symptoms owing to dysphagia on the third postoperative day, but after the symptoms improved he was transferred to the hospital for rehabilitation of dysphagia and dyspnea.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">It is critical to monitor whether muscle relaxation is sufficiently reversed when using sugammadex in ALS patients. Further research is needed to determine the appropriate dose of sugammadex for muscle relaxation reversal.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Hea Rim</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of anesthesiology and pain medicine, Soonchunhyang University Hospital Cheonan, 31, Soonchunhyang 6gil, Dongnam-gu, Cheonan, Chungcheongnam-do, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jinhun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Nan Seol</ForeName><Initials>NS</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>A Joo</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Suro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Kyu Sik</ForeName><Initials>KS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003473">Neuromuscular Nondepolarizing Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>361LPM2T56</RegistryNumber><NameOfSubstance UI="D000077122">Sugammadex</NameOfSubstance></Chemical><Chemical><RegistryNumber>WRE554RFEZ</RegistryNumber><NameOfSubstance UI="D000077123">Rocuronium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003473" MajorTopicYN="N">Neuromuscular Nondepolarizing Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077123" MajorTopicYN="N">Rocuronium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077122" MajorTopicYN="N">Sugammadex</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014515" MajorTopicYN="N">Ureteral Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32011508</ArticleId><ArticleId IdType="pmc">PMC7220140</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000018867</ArticleId><ArticleId IdType="pii">00005792-202001170-00079</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tiryaki E, Horak HA. ALS and other motor neuron diseases. Continuum (Minneapolis, Minn) 2014;20(5 Peripheral Nervous System Disorders):1185&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">25299277</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TP, Stone WA, Hamelberg W. Circulatory collapse following succinylcholine: report of a patient with diffuse lower motor neuron disease. Anesth Analg 1971;50:431&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">5103781</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum KJ, Neigh JL, Strobel GE. Sensitivity to nondepolarizing muscle relaxants in amyotrophic lateral sclerosis: report of two cases. Anesthesiology 1971;35:638&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">5124745</ArticleId></ArticleIdList></Reference><Reference><Citation>Brull SJ, Kopman AF. Current status of neuromuscular reversal and monitoring: challenges and opportunities. Anesthesiology 2017;126:173&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">27820709</ArticleId></ArticleIdList></Reference><Reference><Citation>Vymazal T, Krecmerova M, Bicek V, et al. Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery&#x2014;a series of 117 cases. Ther Clin Risk Manag 2015;11:1593&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4610805</ArticleId><ArticleId IdType="pubmed">26508869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungur Ulke Z, Yavru A, Camci E, et al. Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy. Acta Anaesthesiol Scand 2013;57:745&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23678983</ArticleId></ArticleIdList></Reference><Reference><Citation>Soyoral L, Goktas U, Cegin MB, et al. Successful use of sugammadex for caesarean section in a patient with myasthenia gravis. Braz J Anesthesiol 2017;67:221&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">28236874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelsaka E, Karakaya D, Zengin EC. Use of sugammadex in a patient with amyotrophic lateral sclerosis. Med Princ Pract 2013;22:304&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5586730</ArticleId><ArticleId IdType="pubmed">23075763</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YJ, Jung WS, Son WR, et al. Discordance between train-of-four response and clinical symptoms in a patient with amyotrophic lateral sclerosis. Acta Med Okayama 2014;68:125&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24743788</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo JH, Kim SI, Park SY, et al. Use of sugammadex in a patient with progressive muscular atrophy and in a patient with amyotrophic lateral sclerosis: case report. Medicine 2017;96:e7098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466231</ArticleId><ArticleId IdType="pubmed">28591053</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus T, Beck M, Giess R, et al. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002;25:709&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994965</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta A, Morris S. Myasthenia gravis and sensitivity to muscle relaxants. Anaesthesia 1995;50:574.</Citation><ArticleIdList><ArticleId IdType="pubmed">7618697</ArticleId></ArticleIdList></Reference><Reference><Citation>Donati F. Sugammadex: a cyclodextrin to reverse neuromuscular blockade in anaesthesia. Expert Opin Pharmacother 2008;9:1375&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">18473711</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs-Buder T, Meistelman C, Raft J. Sugammadex: clinical development and practical use. Korean J Anesthesiol 2013;65:495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888841</ArticleId><ArticleId IdType="pubmed">24427454</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008;107:130&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18635478</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A, et al. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex. Minerva Anestesiol 2016;82:735&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">26472231</ArticleId></ArticleIdList></Reference><Reference><Citation>Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth 2015;115:743&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">25935840</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>